What palliative treatment options are recommended for a patient with acute myeloid leukemia in blast phase who is unsuitable for curative therapy?

Palliative Treatment for Blast Crisis in AML

For AML patients in blast phase unsuitable for curative therapy, hypomethylating agents (azacitidine or decitabine) combined with venetoclax represent the preferred palliative treatment option, with azacitidine alone as an alternative if venetoclax is contraindicated. 1, 2

Treatment Algorithm for Unfit Patients

First-Line Palliative Options (in order of preference):

1. Venetoclax-based combinations 2:

   • Venetoclax + azacitidine (preferred)
   • Venetoclax + decitabine
   • Venetoclax + low-dose cytarabine (LDAC)

2. Hypomethylating agent monotherapy 1:

   • Azacitidine: Median survival 10.4 months vs 6.5 months with conventional care 1
   • Particularly advantageous in adverse cytogenetics
   • Decitabine: Median survival 7.7 months vs 5.0 months with LDAC 1
   • Continue for up to 6 cycles to observe maximal response
   • Discontinue after 3 cycles if no response 1

3. Low-dose cytarabine (LDAC) alone 1, 3:

   • CR rates 15-25%
   • Median survival 5-6 months
   • Well-tolerated but inferior outcomes

4. Glasdegib + LDAC (if available) 2

5. Best supportive care 1, 3:

   • Hydroxyurea for cytoreduction
   • Transfusion support
   • Infection management

Targeted Therapy Additions

If specific mutations are present, add targeted agents:

• FLT3-mutated AML: HMA + sorafenib 2
• IDH1-mutated AML: Ivosidenib or HMA alone 2
• IDH2-mutated AML: Enasidenib or HMA alone 2

Key Clinical Considerations

Response Assessment

• Hematologic improvement without CR still provides clinical benefit 1:
  • Reduction in transfusion requirements
  • Improved quality of life
  • HMAs can alter the natural course even without achieving complete remission

Symptom Management Priorities

Leukocytosis control 3:

• Hydroxyurea for excessive blast counts
• Low-dose cytarabine (note: also lowers normal blood counts)

Transfusion support 3:

• Maintain platelets ≥30-50 G/L
• Red cell transfusions for symptomatic anemia
• Note: Erythropoietin has questionable value with extensive marrow infiltration 3

Infection management 3:

• Growth factors (G-CSF) may be tried for febrile neutropenia
• No evidence for continuous prophylactic use

Common Pitfalls to Avoid

1. Premature discontinuation of HMAs: Up to 6 cycles may be needed for maximal response; however, stop after 3 cycles if absolutely no response 1

2. Overlooking mutation testing: Missing opportunities for targeted therapy (FLT3, IDH1/2) that could improve outcomes 2

3. Inadequate supportive care: Underestimating the importance of transfusions and infection management in maintaining quality of life 3

4. Delayed palliative care integration: Early palliative care consultation improves symptom management and addresses psychosocial needs 4, 5, 6

Quality of Life Focus

The 2017 ELN guidelines emphasize that hematologic improvement yields clinical benefit through reduced transfusions and improved quality of life, even without achieving complete remission 1. This is particularly important in the palliative setting where the goal shifts from cure to symptom control and maintaining functional status.

Specific Challenges in AML Blast Phase 4, 6:

• Physical symptoms: fatigue, fevers, activity restriction
• Psychological distress: helplessness, hopelessness, uncertainty
• Caregiver stress
• Frequent hospitalizations and transfusion requirements

Clinical trial enrollment should be strongly considered whenever possible 1, as treatment outcomes remain unsatisfactory in this population and novel approaches are needed.